JTO Clinical and Research Reports (Aug 2022)
Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis
- Christine M. Bestvina, MD,
- Jennifer G. Whisenant, PhD,
- Valter Torri, MD,
- Alessio Cortellini, MD,
- Heather Wakelee, MD,
- Solange Peters, MD, PhD,
- Elisa Roca, MD, PhD,
- Alessandro De Toma, MD,
- Fred R. Hirsch, MD,
- Hirva Mamdani, MD,
- Balazs Halmos, MD,
- Oscar Arrieta, MD,
- Anne-Cecile Metivier, MD,
- Mary J. Fidler, MD,
- Jacobo Rogado, MD,
- Carolyn J. Presley, MD, MHS,
- Celine Mascaux, MD,
- Carlo Genova, MD, PhD,
- Juan Bautista Blaquier, MD,
- Alfredo Addeo, MD,
- Giovanna Finocchiaro, MD,
- Hina Khan, MD,
- Julien Mazieres, MD, PhD,
- Floriana Morgillo, MD, PhD,
- Jair Bar, MD,
- Avinash Aujayeb, MBBS,
- Giannis Mountzios, MD, PhD,
- Vieri Scotti, MD,
- Federica Grosso, MD,
- Erica Geraedts, MD,
- Ardak N. Zhumagaliyeva, MD, PhD,
- Leora Horn, MD,
- Marina Chiara Garassino, MD,
- Javier Baena, MD
Affiliations
- Christine M. Bestvina, MD
- Department of Medicine, University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; Corresponding author. Address for correspondence: Christine Bestvina, MD, Section of Hematology/Oncology, Department of Medicine, University of Chicago Medicine, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637.
- Jennifer G. Whisenant, PhD
- Vanderbilt University Medical Center, Nashville, Tennessee
- Valter Torri, MD
- Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy
- Alessio Cortellini, MD
- Department of Surgery and Cancer, Imperial College London, London, United Kingdom
- Heather Wakelee, MD
- Stanford Cancer Institute, Stanford University, Stanford, California
- Solange Peters, MD, PhD
- Lausanne University Hospital, Lausanne University, Lausanne, Switzerland
- Elisa Roca, MD, PhD
- Thoracic Oncology—Lung Unit, Ospedale Pederzoli, Peschiera d/G, Verona, Italy
- Alessandro De Toma, MD
- Thoracic Oncology Unit, Medical Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy
- Fred R. Hirsch, MD
- Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine Mount Sinai, New York, New York
- Hirva Mamdani, MD
- Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan
- Balazs Halmos, MD
- Division of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York
- Oscar Arrieta, MD
- Thoracic Oncology Unit, Instituto Nacional de Cancerologia (INCan), Mexico City, Mexico
- Anne-Cecile Metivier, MD
- Department of Pneumology, Hopital Foch, Suresnes, France
- Mary J. Fidler, MD
- Department of Hematology, Oncology, and Cell Therapy, Rush University Medical Center, Chicago, Illinois
- Jacobo Rogado, MD
- Seccion de Oncologia Medica, Hospital Universitario Infanta Leonor, Madrid, Spain
- Carolyn J. Presley, MD, MHS
- Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
- Celine Mascaux, MD
- Service De Pneumologie, Hopitaux Universitaires De Strasbourg, Strasbourg, France; Laboratory Streinth (Stress REsponse and INnovative THerapy against Cancer), Inserm UMR_S 1113, IRFAC, ITI InnoVec, Universite De Strasbourg, Strasbourg, France
- Carlo Genova, MD, PhD
- UOC Clinica di Oncologia Medica, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, Genoa, Italy; Dipartimento di Medicina Interna e Specialita Mediche (DIMI), Universita degli Studi di Genova, Genoa, Italy
- Juan Bautista Blaquier, MD
- Thoracic Oncology Section, Centro de Educacion Medica e Investigaciones Clinicas (CEMIC), Buenos Aires, Argentina
- Alfredo Addeo, MD
- University Hospital of Geneva, Geneva, Switzerland
- Giovanna Finocchiaro, MD
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy
- Hina Khan, MD
- The Warren Alpert Medical School of Brown University, Providence, Rhode Island
- Julien Mazieres, MD, PhD
- Toulouse University Hospital, Université Paul Sabatier, Toulouse, France
- Floriana Morgillo, MD, PhD
- Department of Precision Medicine, Medical Oncology and Haematology, Universita degli studi della Campania “L. Vanvitelli,” Naples, Italy
- Jair Bar, MD
- Institute of Oncology, Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel
- Avinash Aujayeb, MBBS
- Respiratory Department, Northumbria Healthcare NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom
- Giannis Mountzios, MD, PhD
- Fourth Department of Medical Oncology and Clinical Trials Unit Henry Dunant Hospital Center, Athens, Greece
- Vieri Scotti, MD
- Department of Oncology, Radiation Therapy Unit, Careggi University Hospital, Florence, Italy
- Federica Grosso, MD
- Mesothelioma and Rare Cancer Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
- Erica Geraedts, MD
- Groene Hart Ziekenhuis, Gouda, The Netherlands
- Ardak N. Zhumagaliyeva, MD, PhD
- Semey Medical University, Center for Nuclear Medicine and Oncology of Semey, Semey, Kazakhstan
- Leora Horn, MD
- Vanderbilt University Medical Center, Nashville, Tennessee
- Marina Chiara Garassino, MD
- Department of Medicine, University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, Illinois
- Javier Baena, MD
- Hospital Universitario 12 de Octubre, Madrid, Spain
- Journal volume & issue
-
Vol. 3,
no. 8
p. 100335
Abstract
Introduction: The Thoracic Centers International coronavirus disease 2019 (COVID-19) Collaboration (TERAVOLT) registry found approximately 30% mortality in patients with thoracic malignancies during the initial COVID-19 surges. Data from South Africa suggested a decrease in severity and mortality with the Omicron wave. Our objective was to assess mortality of patients with thoracic malignancies with the Omicron-predominant wave and evaluate efficacy of vaccination. Methods: A prospective, multicenter observational study was conducted. A total of 28 institutions contributed data from January 14, 2022, to February 4, 2022. Inclusion criteria were any thoracic cancer and a COVID-19 diagnosis on or after November 1, 2021. End points included mortality, hospitalization, symptomatic COVID-19 infection, asymptomatic COVID-19 infection, and delay in cancer therapy. Analysis was done through contingency tables and a multivariable logistic model. Results: We enrolled a total of 346 patients. Median age was 65 years, 52.3% were female, 74.2% were current or former smokers, 86% had NSCLC, 72% had stage IV at time of COVID-19 diagnosis, and 66% were receiving cancer therapy. Variant was unknown for 70%; for those known, Omicron represented 82%. Overall mortality was 3.2%. Using multivariate analysis, COVID-19 vaccination with booster compared with no vaccination had a protective effect on hospitalization or death (OR = 0.30, confidence interval: 0.15–0.57, p = 0.0003), whereas vaccination without booster did not (OR = 0.64, confidence interval: 0.33–1.24, p = 0.1864). Cancer care was delayed in 56.4% of the patients. Conclusions: TERAVOLT found reduced patient mortality with the most recent COVID-19 surge. COVID-19 vaccination with booster improved outcomes of hospitalization or death. Delays in cancer therapy remain an issue, which has the potential to worsen cancer-related mortality.
